VRPX — Virpax Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- $0.35m
- -$1.16m
Annual balance sheet for Virpax Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.055 | 36.8 | 19 | 9.14 | 1.51 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0 | — | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 0.073 | 39.6 | 19.7 | 9.63 | 1.56 |
| Other Long Term Assets | |||||
| Total Assets | 0.465 | 39.6 | 19.7 | 9.63 | 1.56 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.66 | 2.09 | 3.09 | 7.69 | 2.47 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 4.68 | 2.09 | 3.09 | 7.69 | 2.47 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -4.22 | 37.5 | 16.6 | 1.93 | -0.914 |
| Total Liabilities & Shareholders' Equity | 0.465 | 39.6 | 19.7 | 9.63 | 1.56 |
| Total Common Shares Outstanding |